Perspective Back to Top In December 2020, liraglutide was approved by the FDA for treatment of obesity in adolescents
While this type of reaction is common with many subcutaneous injections, some people may be more prone to it because of factors like skin sensitivity or improper injection technique
PubMed Central PMCID: PMC2323325
It does not reset
2024 Case updates December 2024: The Judicial Panel on Multidistrict Litigation overseeing the organization of consolidated federal court lawsuits (called an MDL) ordered that DVT and blood clot injury cases will be excluded from the MDL
In the Rybelsus trials, gastrointestinal complaints rose with dose: for example, nausea was reported by about 6 percent of people on placebo, 11 percent on the 7 mg tablet, and 20 percent on the 14 mg tablet, and the majority of nausea, vomiting, and diarrhea occurred during dose escalation rather than steady state